| Combination of | |
|---|---|
| Salbutamol | Beta2-adrenergic agonist |
| Budesonide | Corticosteroid |
| Clinical data | |
| Trade names | Airsupra |
| Other names | PT027, albuterol/budesonide |
| AHFS/Drugs.com | Multum Consumer Information |
| License data | |
| Routes of administration |
Inhalation |
| ATC code |
|
| Legal status | |
| Legal status |
|
Salbutamol/budesonide, sold under the brand name Airsupra, is a fixed-dose combination medication for the treatment of bronchoconstriction and asthma. It is a combination of salbutamol sulfate (albuterol sulfate), a short-acting beta2-adrenergic agonist, and budesonide, an inhaled corticosteroid. It is inhaled using a pressurized metered-dose inhaler.
The most common side effects include headache, oral candidiasis, cough, and difficulty speaking.
Salbutamol/budesonide was approved for medical use in the United States in January 2023. It is the first combination of an inhaled corticosteroid and a short-acting beta-agonist to be approved by the US Food and Drug Administration (FDA). It is the first product containing an inhaled corticosteroid to be approved by the FDA as a reliever treatment (rather than as a controller) for asthma.
Medical uses
Salbutamol/budesonide is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks.
History
The efficacy of salbutamol/budesonide to reduce the risk of severe asthma attacks was evaluated in participants with moderate to severe asthma in MANDALA (NCT03769090), a randomized, double-blind, multicenter study.
Further reading
- Papi A, Chipps BE, Beasley R, Panettieri RA, Israel E, Cooper M, et al. (June 2022). "Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma". The New England Journal of Medicine. 386 (22): 2071–2083. doi:10.1056/NEJMoa2203163. PMID 35569035.
External links
- Clinical trial number NCT03769090 for "A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma (MANDALA)" at ClinicalTrials.gov
